|
|
|
|
| Professor Carol Kellogg | Professor Peter Como |
| Office: Meliora 186 | Office: Meliora 171 |
| Telephone: 5-4801 | Telephone: 5-8726 |
| Office Hours: 4:00-4:30, M &W or by appointment | Office Hours: 4:15-4:45, M & W or by appointment |
| e-mail: kellogg@bcs.rochester.edu | e-mail: pcomo@mct.rochester.edu |
Course Intent: The objective of this course is to present current understanding of biologic mechanisms involved in the etiology and pathology of various brain disorders, including those disorders generally classified as "mental disorders." Basic concepts of neurobiology will be presented coincidentally with discussion of the clinical presentation and management of the various disorders.
Texts: Andreasen, Nancy C. Brave New Brain: Conquering Mental Illness in the Era of the Geneome, Oxford University Press, 2001. This book provides clear descriptions of various mental illnesses and also places these illnesses in the context of biologic disorders. REQUIRED
Pliszka, S.R. Neuroscience for the Mental Health Clinician, The Guilford Press. 2003. This book provides more details on basic mechanisms of neurotransmission. REQUIRED
Charney, Dennis S., Nestler, Eric J., Bunney, Benjamin S., Neurobiology of Mental Illness, Oxford University Press, 1999. We are using the softcover edition of this text. This is an edited text providing current information on the understanding of neurobiologic mechanisms contributing to mental disorders. It is quite detailed. Specific chapters from this book will be required reading for all students, and those chapters will be put on electronic reserve. For students registered for BCS 546, this book is required.
Additional readings that are assigned will be placed on electronic reserve. Readings on electronic reserve are marked by an * in the class schedule.
Course Evaluation: Five exams accounting for 100% of the final grade will be given. Both take-home and in-class exams are scheduled. The in-class exams may include discussion questions for which study questions will be handed out prior to the in-class exams. The following ranges provide a general guideline for estimating final grades:
| > 90%=A-/A | 78%-89%= B-/B/B+ | 65%-77%= C-/C/C+ |
| Jan. 15 |
Introduction Defining Mental Illness: Andreasen, Ch. 1-3 & 7 | P. Como |
| UNIT 1: Basic Concepts of Neurotransmitter Function | ||
| Jan. 20 | No Class: Martin Luther King Day | |
| Jan. 22 |
Chemical Messenger Systems: Pliszka, Ch. 4, Andreasen, pp. 75-86 and review pp. 41-75; Charney, Ch.2 | C. Kellogg |
| Jan. 27 |
Transmitter Role in Regulating Neural Activity: Pliszka, Ch.3 pp. 32-50. Charney, Ch.3, 4 | C. Kellogg |
| Jan. 29 |
Mechanisms of Neural Plasticity: Charney, Ch.* 5, *6; Andreasen, Ch. 5 | C. Kellogg |
| Feb. 3 | Hormone: Brain interactions and Stress-Responsive Neural MechanismsC. Kellogg | |
| Take-Home Problem Set: Due in Feb. 10 | ||
| Unit 2: Neurobiology of Psychoses | ||
| Feb. 5 |
The major psychoses: Andreasen, Ch. 8, pp. 186-197; Pliszka, Ch.12, pp. 225-239 Charney, Ch. 15 | P. Como |
| Feb. 10 |
Neurobiology of Psychoses: Pliszka, Ch. 12 pp. 225-239; Ch. 8, pp. 136-141; Andreasen, pp. 197-210; Charney, *Ch. 18, 19, 20 | C. Kellogg |
| Feb. 12 |
Clinical management of psychoses: Andreasen, pp. 210-214; Charney, *Ch. 22 | P. Como |
| UNIT 3: Mood Disorders | ||
| Feb. 17 |
Classification of Mood Disorders: Andreason, Ch.9, pp. 215-234; Pliszka, Ch. 11, pp. 200-216 Charney, Ch. 23 | P. Como
|
| Feb. 19 |
Neurobiology of Mood Disorders: Andreason, Ch. 9, pp. 234-246; Pliszka, Ch. 11, pp. 200-216; Charney, *Ch. 26; Charney, Ch. 27 | C. Kellogg |
| Feb. 24 |
Clinical management of Mood Disorders: Andreason, Ch. 9; pp. 246-252; Charney, *Ch. 31 | P. Como |
| Take-Home Exam over UNITS 2 and 3: Due in March 3 | ||
| UNIT 4: Anxiety Disorders | ||
| Feb. 26 |
Classification of anxiety disorders: Andreasen, Ch. 11; Pliszka, Ch.11, pp. 216-220; Charney, Ch. 32 | P. Como |
| March 3 |
Neurobiology of Anxiety Disorders Charney, Ch. *34, *36; Charney, Ch. 35; Pliszka, Ch. 5, Ch.11, pp. 216-220 | C. Kellogg |
| March 5 | Description and Neurobiology of Obsessive-Compulsive Disorder; Charney, *Ch. 37 | P. Como |
| March 10, 12 | Spring Break | |
| March 17 |
Clinical Management of Anxiety Disorders Andreasen, pp. 311-314; Charney, *Ch. 39 | P. Como |
| Unit 5: Substance Abuse | ||
| March 19 |
Neural Basis of addiction: Charney, Chs. *41, *43; Pliszka, Ch.10, pp. 185-192 | C. Kellogg |
| March 24 | The Hijacked Brain: Video | C. Kellogg |
| March 26 | In-Class Exam over UNITS 4 and 5 | |
| Unit 6: Neurodegenerative Disorders | ||
| March 31 |
Neural Mechanisms of Cell Death *Leist, M. and Nicotera, P. (1998) Apoptosis, excitotoxicity, and neuropathology. Exp. Cell Res. 239:183-201. | C. Kellogg |
| April 2 |
Clinical Description of Basal Ganglia Disorders *Chapter 10, ParkinsonŐs Disease. In: P.G. Strange, Brain Biochemistry and Brain Disorders, Oxford Press (1994), pp. 161-186. *Biglan, K.M., Shoulson, I. Chapter 14, HuntingtonŐs disease. In: J.Jankovic, Ed., ParkinsonŐs disease and movement disorders, In Press. | P. Como |
| April 7 |
Neuropathology of Basal Ganglia and Cortical Degenerative
Disorders *Cattaneo, E., Rigamonti, D., Goffredo, D., Zuccato, C. Squitieri, F., Sipione, S., (2001) Loss of normal huntingtin function: new developments in HuntingtonŐs disease research, Trends in Neurosci., 24: 182-188. *Lozano, A., Lang, A., Hutchison, W.D., Dostrovsky, J.O. (1998) New developments in understanding the etiology of ParkinsonŐs disease and in its treatment. Current Opinion in Neurobiol., 8: 783-790 *Felician O, Sandson TA. (1999) The neurobiology and pharmacotherapy of Alzheimer's disease. J Neuropsychiatry Clin Neurosci, 11:19-31. | C. Kellogg |
| April 9 |
Clinical Description of Cortical Degenerative Disorders Andreason, Ch. 10; Charney, *Ch. 46 | Dr. Mark Mapstone |
| April 14 |
Clinical Management of Degenerative Disorders *Mayeux R, Sano M. Treatment of Alzheimer's disease. (1999), New England Journal of Medicine; 341:1670-1679. *Felician O, Sandson TA. The neurobiology and pharmacotherapy of Alzheimer's disease. J Neuropsychiatry Clin Neurosci, 1999; 11:19-31. | P. Como |
| April 16 |
Issues of Genetic Risk *Hayden MR. Predictive testing for Huntington's disease: the calm after the storm. Lancet, 2000; 356:1944-1945. *Hall MA, Rich SS. Laws restricting health insurer's use of genetic information: impact on genetic discrimination. Am J Hum Genet., 2000; 66:293-307. | P. Como |
| April 21 | In Class Exam over Unit 6 | |
| Unit 7: Sex-Related Disorders | ||
| April 23 |
Sex-related Neurobiology *Breedlove, S.M., Cooke, B.M., Jordan, C.L. (1999) The orthodox view of brain sexual differentiation. Brain Behav Evol, 54: 8-14. *Pilgrim, C. & Hutchison, J.B. (1994) Developmental regulation of sex differences in the brain: Can the role of gonadal steroids be redefined. Neuroscience, 60: 843-855. | C. Kellogg |
| April 28 |
Eating Disorders *Kaye, W.H., Klump, K.L., Frank, G.K.W., Strober, M. (2000) Anorexia and Bulimia Nervosa, Ann. Re. Med., 551:299-313; Charney, Ch. 68 | |
| April 30 |
Attention Deficit Disorders: Pliszka, Ch. 9; Charney, Ch. 60 TAKE-HOME FINAL HANDED OUT | P. Como |
| May 9 | TAKE-HOME FINAL EXAM DUE BY 4:00 pm | |
|
Last modified: 2/18/2003
questions and comments about this site |